Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended December 31, 2002, for Celsion Corporation (Note: The input metadata referenced "Imunon, Inc.", but the filing text explicitly identifies the registrant as Celsion Corporation). Celsion is a clinical-stage biotechnology company focused on developing thermotherapy systems for the treatment of cancer and benign prostatic hyperplasia (BPH). The company has no product sales and continues to incur operating losses while advancing its technologies through clinical trials.
Key Financial Metrics
| Metric | Q1 2003 (Ended Dec 31, 2002) | Q1 2002 (Ended Dec 31, 2001) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(1,934,821) | $(1,653,408) |
| Net Loss Attributable to Common Stockholders | $(1,988,134) | $(1,676,358) |
| Net Loss Per Share (Basic) | $(0.02) | $(0.02) |
| Cash and Cash Equivalents (Ending) | $1,050,606 | $4,335,194 |
| Working Capital | $993,313 | Not explicitly stated (Calculated: ~$735k prior period) |
| Total Debt (Notes Payable) | $500,000 | $0 |
| Accumulated Deficit | $(45,808,217) | Not stated |
Material Changes vs. Prior Period
- Operating Expenses: Total operating expenses increased by approximately 16% to $1,937,472 from $1,664,468 in the prior year quarter.
- General and Administrative (G&A): G&A expenses rose 55% to $840,044. This increase was primarily driven by $105,000 in compensation for non-employee directors (recorded in this quarter vs. the prior fiscal year's Q3) and higher legal fees related to a Special Shareholder's Meeting and patent expenses.
- Research and Development (R&D): R&D expenses decreased slightly by 2% to $1,097,428, attributed to lower material and design costs, partially offset by increased salaries for new clinical and engineering personnel.
- Financing Activities: The company raised $2,003,000 in net cash from financing activities, including $1,503,000 from stock issuances and a new $500,000 note payable to Boston Scientific Corporation.
- Cash Flow: Net cash used in operating activities was $1,880,919, compared to $1,886,100 in the prior year. The company ended the period with a net cash increase of $121,787 due to financing inflows.
Guidance, Outlook, and Risks
- Strategic Partnership: On January 21, 2003, Celsion entered an agreement with Boston Scientific Corporation. Boston Scientific purchased 9,375,354 shares for an initial $5,000,000 investment and agreed to invest an additional $10 million upon meeting milestones. This funding is expected to repay the $500,000 note and fund operations through fiscal year 2003.
- Revenue Outlook: No product revenues are expected until regulatory approvals are obtained for new equipment currently in pivotal Phase II clinical testing. The company anticipates expending approximately $8,500,000 in fiscal 2003 for clinical testing and overhead.
- Liquidity Risk: The company has an accumulated deficit of $45.8 million and relies on equity financing and strategic partnerships. Management states that if adequate funds are not available, they may be forced to delay operations or relinquish rights to technologies.
- Regulatory Risk: Future profitability depends on obtaining governmental approvals for thermotherapy systems. Failure to secure funding or approvals could result in a breach of licensing agreements and loss of license rights.
Investor Verification Checklist
- Verify the status and timeline of the pivotal Phase II clinical trials for the breast cancer and BPH treatment systems.
- Confirm the terms and milestone triggers for the additional $10 million investment from Boston Scientific Corporation.
- Monitor the company's cash burn rate against the projected $8.5 million expenditure for fiscal 2003.
- Review the impact of the $500,000 note payable to Boston Scientific and its repayment schedule.
- Assess the dilution impact of recent private placements and the January 2003 stock issuance to Boston Scientific.